Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 60 results.
User Information
Export Records
  1. 1.   Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
  2. Moore, L. E.; Nickerson, M. L.; Brennan, P.; Toro, J. R.; Jaeger, E.; Rinsky, J.; Han, S. S.; Zaridze, D.; Matveev, V.; Janout, V.; Kollarova, H.; Bencko, V.; Navratilova, M.; Szeszenia-Dabrowska, N.; Mates, D.; Schmidt, L. S.; Lenz, P.; Karami, S.; Linehan, W. M.; Merino, M.; Chanock, S.; Boffetta, P.; Chow, W. H.; Waldman, F. M.; Rothman, N.
  3. Plos Genetics. 2011, Oct; 7(10): 13.
  1. 2.   Carminomycin I Is an Apoptosis Inducer That Targets the Golgi Complex in Clear Cell Renal Carcinoma Cells
  2. Woldemichael, G. M.; Turbyville, T. J.; Linehan, W. M.; McMahon, J. B.
  3. Cancer Research. 2011, Jan; 71(1): 134-142.
  1. 3.   Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production
  2. Zhang, S. L.; Readinger, J. A.; DuBois, W.; Janka-Junttila, M.; Robinson, R.; Pruitt, M.; Bliskovsky, V.; Wu, J. Z.; Sakakibara, K.; Patel, J.; Parent, C. A.; Tessarollo, L.; Schwartzberg, P. L.; Mock, B. A.
  3. Blood. 2011, Jan; 117(4): 1228-1238.
  1. 4.   Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications
  2. Kwon, M. J.; Kim, S. S.; Choi, Y. L.; Jung, H. S.; Balch, C.; Kim, S. H.; Song, Y. S.; Marquez, V. E.; Nephew, K. P.; Shin, Y. K.
  3. Carcinogenesis. 2010, Jun; 31(6): 974-983.
  1. 5.   Molecular Diagnosis and Therapy of Kidney Cancer
  2. Linehan, W. M.; Bratslavsky, G.; Pinto, P. A.; Schmidt, L. S.; Neckers, L.; Bottaro, D. P.; Srinivasan, R.
  3. Annual Review of Medicine. 2010, Feb; 61: 329-343.
  1. 6.   BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports
  2. Toro, J. R.; Wei, M. H.; Glenn, G. M.; Weinreich, M.; Toure, O.; Vocke, C.; Turner, M.; Choyke, P.; Merino, M. J.; Pinto, P. A.; Steinberg, S. M.; Schmidt, L. S.; Linehan, W. M.
  3. Journal of Medical Genetics. 2008 45(6): 321-331.
  1. 7.   Proteomic analysis of protein expression changes in a model of gliomagenesis
  2. McBee, J. K.; Yu, L. R.; Kinoshita, Y.; Uo, T.; Beyer, R. P.; Veenstra, T. D.; Morrison, R. S.
  3. Proteomics Clinical Applications. 2007, Nov; 1(11): 1485-1498.
  1. 8.   Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics
  2. Linehan, W. M.; Pinto, P. A.; Srinivasan, R.; Merino, M.; Choyke, P.; Choyke, L.; Coleman, J.; Toro, J.; Glenn, G.; Vocke, C.; Zbar, B.; Schmidt, L. S.; Bottaro, D.; Neckers, L.
  3. Clinical Cancer Research. 2007, Jan; 13(2): 671S-679S.
  1. 9.   Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression
  2. Woldemichael, G. M.; Vasselli, J. R.; Gardella, R. S.; McKee, T. C.; Linehan, W. M.; McMahon, J. B.
  3. Journal of Biomolecular Screening. 2006, Sep; 11(6): 678-687.
  1. 10.   Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells
  2. de la Pena, L.; Burgan, W. E.; Carter, D. J.; Hollingshead, M. G.; Satyamitra, M.; Camphausen, K.; Tofilon, P. J.
  3. Molecular Cancer Therapeutics. 2006, Jun; 5(6): 1504-1510.
  1. 11.   Lsh controls silencing of the imprinted Cdkn1c gene
  2. Fan, T.; Hagan, J. P.; Kozlov, S. V.; Stewart, C. L.; Muegge, K.
  3. Development. 2005, FEB; 132(4): 635-644.
  1. 12.   Birt-Hogg-Dube syndrome, a genodermatosis that increases risk for renal carcinoma
  2. Schmidt, L. S.
  3. Current Molecular Medicine. 2004, DEC; 4(8): 877-885.
  1. 13.   Intraspecific mating with CzechII/Ei mice rescue lethality associated with loss of function mutations of the imprinted genes, Igf2r and Cdkn1c
  2. Hagan, J. P.; Kozlov, S. V.; Chiang, Y. S.; Sewell, L.; Stewart, C. L.
  3. Genomics. 2004, NOV; 84(5): 836-843.
  1. 14.   The importance of genome architecture in cancer susceptibility - Location, location, location
  2. Reilly, K. M.
  3. Cell Cycle. 2004, NOV; 3(11): 1378-1382.
  1. 15.   Genetic basis of cancer of the kidney: Disease specific approaches to therapy
  2. Linehan, W. M.; Vasselli, J.; Srinivasan, R.; Walther, M. M.; Merino, M.; Choyke, P.; Vocke, C.; Schmidt, L.; Isaacs, J. S.; Glenn, G.; Toro, J.; Zbar, B.; Bottaro, D.; Neckers, L.
  3. Clinical Cancer Research. 2004, SEP 15; 10(18, Part 2 Suppl. S): 6282S-6289S.
  1. 16.   Reduced Fhit protein expression in nickel-transformed mouse cells and in nickel-induced murine sarcomas
  2. Kowara, R.; Salnikow, K.; Diwan, B. A.; Bare, R. M.; Waalkes, M. P.; Kasprzak, K. S.
  3. Molecular and Cellular Biochemistry. 2004 255(1-2): 195-202.
  1. 17.   A germ-line insertion in the Birt-Hogg-Dube (BHD) gene gives rise to the Nihon rat model of inherited renal cancer
  2. Okimoto, K.; Sakurai, J.; Kobayashi, T.; Mitani, H.; Hirayama, Y.; Nickerson, M. L.; Warren, M. B.; Zbar, B.; Schmidt, L. S.; Hino, O.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2004 101(7): 2023-2027.
  1. 18.   Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line
  2. Pompeia, C.; Hodge, D. R.; Plass, C.; Wu, Y. Z.; Marquez, V. E.; Kelley, J. A.; Farrar, W. L.
  3. Cancer Research. 2004 64(10): 3465-3473.
  1. 19.   The von Hippel-Lindau gene and protein in tumorigenesis and angiogenesis: A potential target for therapeutic designs
  2. Shiao, Y. H.
  3. Current Medicinal Chemistry. 2003 10(22): 2461-2470.
  1. 20.   VHL down-regulation and differential localization as mechanisms in tumorigenesis
  2. Shiao, Y. H.; Forsti, A.; Egevad, L.; Anderson, L. M.; Lindblad, P.; Hemminki, K.
  3. Kidney International. 2003 64(5): 1671-1674.
  1. 21.   Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection
  2. Kuzmin, I.; Liu, L. M.; Dammann, R.; Geil, L.; Stanbridge, E. J.; Wilczynski, S. P.; Lerman, M. I.; Pfeifer, G. P.
  3. Cancer Research. 2003 63(8): 1888-1893.
  1. 22.   An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies
  2. Protopopov, A.; Kashuba, V.; Zabarovska, V. I.; Muravenko, O. V.; Lerman, M. I.; Klein, G.; Zabarovsky, E. R.
  3. Cancer Research. 2003 63(2): 404-412.
  1. 23.   Epigenetic inactivation of RASSF1A in head and neck cancer
  2. Dong, S. M.; Sun, D. I.; Benoit, N. E.; Kuzmin, I.; Lerman, M. I.; Sidransky, D.
  3. Clinical Cancer Research. 2003 9(10, Part 1): 3635-3640.
  1. 24.   Of mice and MEN1: Insulinomas in a conditional mouse knockout
  2. Crabtree, J. S.; Scacheri, P. C.; Ward, J. M.; McNally, S. R.; Swain, G. P.; Montagna, C.; Hager, J. H.; Hanahan, D.; Edlund, H.; Magnuson, M. A.; Garrett-Beal, L.; Burns, A. L.; Ried, T.; Chandrasekharappa, S. C.; Marx, S. J.; Spiegel, A. M.; Collins, F. S.
  3. Molecular and Cellular Biology. 2003 23(17): 6075-6085.
  1. 25.   Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas
  2. Senchenko, V.; Liu, J.; Braga, E.; Mazurenko, N.; Loginov, W.; Seryogin, Y.; Bazov, I.; Protopopov, A.; Kisseljov, F. L.; Kashuba, V.; Lerman, M. I.; Klein, G.; Zabarovsky, E. R.
  3. Oncogene. 2003 22(19): 2984-2992.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel